FDA Approves Tecvayli for Relapsed Multiple Myeloma


Tecvayli Bispecific Engager Approved by FDA for Treatment of Relapsed Myeloma; COVID-19 Subvariants Raise Concerns of Winter Surge In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie shares significant developments and relevant news—a mixed bag of good and bad news— with the myeloma community: the FDA approval of Tecvayli (teclistamab-cqyv); mounting concerns about new omicron subvariants and the possibility of a winter surge; and a series of ongoing major projects in his home country, Scotland to accelerate water reclamation in the country’s precious peat bogs and to help fight climate change. Dr. Durie advises to always keep a watchful eye on the news for useful and valuable information.


FDA Approves Tecvayli (teclistamab-cqyv) for Relapsed or Refractory Multiple Myeloma On Tuesday, October 25, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Tecvayli™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Tecvayli is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment. To learn more, read the press release.


IMF Virtual Regional Community Workshop (RCW)—Pacific Northwest States This IMF Virtual Regional Community Workshop (RCW)—Pacific Northwest States will take place on Saturday, November 19, from 10 a.m. PST to 12:30 p.m. PST. Guest speakers include Craig Cole, MD (Michigan State University, Karmanos Cancer Institute—Detroit, MI) and Amrita Krishnan, MD (City of Hope Comprehensive Cancer Center—Duarte, CA). IMF Nurse Leadership Board (NLB) Member Sandra Rome, RN, MN, AOCN®, CNS will talk about managing side effects and symptoms of myeloma and treatments. After each presentation with the experts, attendees will have ample time to ask questions.


An Interview with Support Group Leader Valarie Traynham In this "A Day in the Life" podcast, 7-year myeloma survivor Valarie Traynham shares her myeloma story. She talks about the shock of receiving a myeloma diagnosis, becoming a support group leader, and the importance of addressing disparities in healthcare. She believes that "knowledge is power, but you have to take that knowledge and do something with it." Get to know more about Valarie’s myeloma journey by listening to the podcast.


Scip & Savor for a Cure Fundraiser Benefits the IMF and Family Reach The Scip & Savor for a Cure Fundraiser was held on Saturday, October 15 at the residence of Fatima and Jimmy Scipione in Medfield, MA. Thanks to the kind generosity of sponsors, benefactors, and attendees and to the gastronomic participation of world-renowned chefs, Andy Husbands and Iron Chef Ming Tsai, the Scipiones were able to raise more than $30,000. All proceeds from the successful event will equally benefit the IMF and Family Reach—a nonprofit organization dedicated to removing the financial barriers standing between cancer patients and their treatment. To know more about this fundraising event, read the press release.

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Ongoing & Upcoming Events

Donate Now
Mackenzie’s March for Myeloma

Donate Now
Christmas in the City

Webinar Replays

Watch the Replay
The M-Power Project Virtual Meeting: New York City 

Watch the Replay
Facebook Live: Do You Know Myeloma Research? 

Watch the Replay
Living Well with Myeloma Webinar: Psychosocial Care | Common Support Needs and Coping Skills

See also, all of our events.

Tecvayli Bispecific Engager Approved by FDA for Treatment of Relapsed Myeloma; COVID-19 Subvariants Raise Concerns of Winter Surge

FDA Approves Tecvayli (teclistamab-cqyv) for Relapsed or Refractory Multiple Myeloma

IMF Virtual Regional Community Workshop (RCW)—Pacific Northwest States

An Interview with Support Group Leader Valarie Traynham

Scip & Savor for a Cure Fundraiser Benefits the IMF and Family Reach

Online Patient Forum

Clinical Trial Fact Sheets

Ongoing & Upcoming Events

Webinar Replays

We Thank Our Sponsors: